Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Invesco SP SmallCap Health Care ETF (PSCH), a passively managed exchange traded fund launched on 04/07/2010.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.
Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Broad is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 13, placing it in bottom 19%.
The fund is sponsored by Invesco. It has amassed assets over $398.80 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Broad segment of the equity market. PSCH seeks to match the performance of the S&P SmallCap 600 Capped Health Care Index before fees and expenses.
This Index is comprised of common stocks of U.S. healthcare companies.These are companies that are principally engaged in the business of providing healthcare-related products & services, including biotechnology, pharmaceuticals, medical technology and supplies & facilities and this Index is a subset of the S&P SmallCap 600 Index.
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.29%, making it one of the least expensive products in the space.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
Looking at individual holdings, Momenta Pharmaceuticals Inc (MNTA) accounts for about 6.89% of total assets, followed by Neogenomics Inc (NEO) and Neogen Corp (NEOG).
The top 10 holdings account for about 37.78% of total assets under management.
Performance and Risk
So far this year, PSCH has added about 8.29%, and was up about 22.34% in the last one year (as of 10/16/2020). During this past 52-week period, the fund has traded between $88.57 and $139.93.
The ETF has a beta of 1.14 and standard deviation of 27.83% for the trailing three-year period, making it a high risk choice in the space. With about 74 holdings, it effectively diversifies company-specific risk.
Invesco SP SmallCap Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PSCH is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR ETF (XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $11.81 billion in assets, Health Care Select Sector SPDR ETF has $23.74 billion. VHT has an expense ratio of 0.10% and XLV charges 0.13%.
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Invesco SP SmallCap Health Care ETF (PSCH): ETF Research Reports
Neogen Corporation (NEOG): Free Stock Analysis Report
NeoGenomics, Inc. (NEO): Free Stock Analysis Report
Health Care Select Sector SPDR ETF (XLV): ETF Research Reports
Vanguard Health Care ETF (VHT): ETF Research Reports
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.